MapLight Therapeutics, Inc.
NASDAQ:MPLTBiotechnology
+$0.39 today
- Market cap
- $283.41M
- Beta
- 2.65
- P/E (TTM)
- -2.8
- EPS (TTM)
- -$4.41
Volume 0.42M
Average 0.73M
MPLT Other Non-current Liabilities
Long-term obligations not reported separately, such as lease or pension liabilities.
MapLight Therapeutics, Inc.NASDAQ: MPLT
Other Non-current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Other non-current liabilities remains negative
Q1 FY2026 other non-current liabilities was $0, compared with $0 a year earlier.
Context
- Other non-current liabilities amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Other non-current liabilities increased in 0 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Non-current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Other Non-current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
Other Non-current Liabilities vs competitors
How MPLT compares with its peers on the latest reported figures
- MPLT's Mar 2026 other non-current liabilities of $0 is the 8th highest of the 11 companies compared; the peer median is $6.73M.
- Other non-current liabilities amounts to 0.0% of total assets for MPLT, versus a peer median of 2.7%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $292.69B | +487717.0% | +32.5% | 307.8% | |
NMRANeumora Therapeutics, Inc. Common Stock | Mar 2026 | $52.96M | — | -59.9% | 34.4% |
| Mar 2026 | $25.01M | -42.5% | +24.4% | 9.0% | |
| Mar 2026 | $16.22M | — | +114.0% | 5.9% | |
| Mar 2026 | $11.61M | +1161000.0% | — | 5.1% | |
DFTXDefinium Therapeutics, Inc. | Sep 2026 | $1.86M | +258.0% | +226.1% | 0.2% |
LBRXLB Pharmaceuticals Inc Common Stock | Mar 2026 | $1.14M | -40.6% | -62.6% | 0.3% |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
RAPPRapport Therapeutics, Inc. Common Stock | Mar 2026 | $0 | — | — | 0.0% |
| Dec 2025 | $0 | — | — | 0.0% | |
| Peer median (excluding MPLT) | $6.73M | +258.0% | +28.4% | 2.7% | |
Competitors are the stored peer set for MPLT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
MapLight Therapeutics, Inc.
NASDAQ:MPLT
Intrinsic Alpha fair value
Locked
Current Price
$6.65
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.